“Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate-to-Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s79. Accessed April 16, 2025. https://skin.dermsquared.com/skin/article/view/1837.